Eton Pharmaceuticals, Inc. (ETON)

$2.61

-0.01 (-0.38%)
Rating:
Recommendation:
-
Symbol ETON
Price $2.61
Beta 1.426
Volume Avg. 0.12M
Market Cap 65.836M
Shares () -
52 Week Range 2.47-6.72
1y Target Est -
DCF Unlevered ETON DCF ->
DCF Levered ETON LDCF ->
ROE -62.00% Strong Sell
ROA -45.04% Strong Sell
Operating Margin -
Debt / Equity 73.32% Buy
P/E -
P/B 4.93 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ETON news


Mr. Sean E. Brynjelsen
Healthcare
Biotechnology
NASDAQ Global Market

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.